Collaborative Treatment Considerations for the Optometrist in Relapsed/Refractory Multiple Myeloma: MITIGATING AND MANAGING OCULAR ADVERSE EVENTS

This CEC Oncology Community Connections will provide an overview of the current treatment landscape for multiple myeloma, guiding attendees through an incisive overview of the clinical considerations involved when selecting therapies for the heavily treated multiple myeloma patient. The rationale for anti–B-cell maturation antigen (BCMA) targeted therapies will be explored, and how to mitigate the unique adverse effects seen with these agents. Finally, strategies to individualize therapy will be discussed, including when to refer patients on to clinical trials for further treatment options.

1. Review the patient, disease, and treatment factors prescribers consider when managing patients with relapsed/refractory multiple myeloma. 
2. Discuss the newer BCMA-targeted immunotherapies for relapsed/refractory multiple myeloma, including their mechanism of action and key efficacy and safety data from pivotal clinical trials. 
3. Discuss common adverse effects seen with recently approved anti-BCMA therapies and explore appropriate monitoring and mitigation strategies to combat these while optimizing therapy. 
4. Examine synergistic strategies for challenging patient cases using BCMA-targeted immunotherapies, with a focus on optometrist collaborative approaches with the oncologist and others on the patient care team. 

Supported through an independent educational grant from GlaxoSmithKline.

This educational initiative is targeted to optometrists attending local/state association meetings who help manage patients with relapsed/refractory multiple myeloma. 

Planners:
Candice Gillett, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Susan Yarborough, CHCP–has no relevant financial relationships to disclose in relation to the content of this activity. 

Faculty:
Soroosh Behshad, MD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity. 

Reviewers:
Scott J. Hershman, MD, FACEHP, CHCP–has no relevant financial relationships to disclose in relation to the content of this activity.
Paul Karpecki, OD, FAAO–has disclosed that he is an advisor or consultant to Alcon, Aldeyra, Allergan/Abbvie, Ametek, Atlas Medical, Avellino Labs, Azura, Bausch + Lomb, BioTissue, Blephex, Bruno Pharmaceuticals, Cambium, Dompe, GoBiquity, Haag Streit, Hilco, iCare USA, Imprimis, Johnson & Johnson Vision, Kala Pharmaceuticals, KEPLR Vision, Kiora Pharmaceuticals, Konan Medical, LenTechs, Neurolens, Novartis, Oasis Medical, Oculus, OcuSoft, Optase, Oyster Point Medical, Rendia, RVL Pharmaceuticals, RxSight, Science Based Health, Sentiss Pharmaceuticals, Sight Sciences, Sun Pharmaceuticals, Surface Pharmaceuticals, Tarsus Medical, Thea, Visant Medical/Stepwise, and Vital Tears. He is also on the speakers bureau for Mallinckrodt and has stock options in Silk Technologies and SleepTite. 

CEC Staff/Planners:
Katherine A. Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity. 

*All relevant financial relationships have been mitigated. 

Unlabeled Use Disclosure  

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, and Creative Educational Concepts do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.